A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

Summary

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.

Eligibility

Age range

Not specified

Sex

All

Healthy volunteers

No

Interventions

• Drug
  lunsekimig

  Pharmaceutical form: solution for injection Route of administration: subcutaneous

• Drug
  Mometasone furoate nasal spray (MFNS)

  Pharmaceutical form: Intranasal spray Route of administration: intranasal

Locations (24)